Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LS301 Uptake in GI Tumor Surgery
NCT04105062Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Peptide-Drug Conjugates
01
Overview
Phase 2, single-blind trial of ls301 in pancreatic cancer (PC), liver cancer, gastric cancer (GC) and 2 more (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Incidence of related adverse events per patient, Optimal imaging dose of LS301 and 1 more. Planned start Dec 2021; status: withdrawn.
02
Drugs
ls301
03
Conditions
pancreatic cancer (PC)liver cancergastric cancer (GC)gastrointestinal stromal tumor (GIST)metastatic cancer
Beyond the preview
Go deeper on NCT04105062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105062.